SI2525812T1 - Antikoagulantni antidoti - Google Patents

Antikoagulantni antidoti

Info

Publication number: SI2525812T1
Authority: SI; Slovenia
Prior art keywords: antidotes; anticoagulant; anticoagulant antidotes
Prior art date: 2010-01-20

Application number

SI201131156A

Other languages

English (en)

Inventor

Ryn Joanne Van

John Edward Park

Norbert Hauel

Ulrich Kunz

Tobias Litzenburger

Keith Canada

Sanjaya Singh

Alisa Waterman

Original Assignee

Boehringer Ingelheim International Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-01-20

Filing date

2011-01-20

Publication date

2017-05-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42061991&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2525812(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-01-20 Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh

2017-05-31 Publication of SI2525812T1 publication Critical patent/SI2525812T1/sl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Cell Biology (AREA)
Pathology (AREA)
Mycology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Toxicology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SI201131156A 2010-01-20 2011-01-20 Antikoagulantni antidoti SI2525812T1 (sl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP10151239		2010-01-20
US38391410P	2010-09-17	2010-09-17
PCT/EP2011/050749 WO2011089183A2 (en)	2010-01-20	2011-01-20	Anticoagulant antidotes
EP11703410.8A EP2525812B1 (en)	2010-01-20	2011-01-20	Anticoagulant antidotes

Publications (1)

Publication Number	Publication Date
SI2525812T1 true SI2525812T1 (sl)	2017-05-31

Family

ID=42061991

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI201131156A SI2525812T1 (sl)	2010-01-20	2011-01-20	Antikoagulantni antidoti

Country Status (43)

Country	Link
US (3)	US8486398B2 (sl)
EP (2)	EP3195876A1 (sl)
JP (2)	JP5575923B2 (sl)
KR (1)	KR101781787B1 (sl)
CN (1)	CN102711813B (sl)
AP (1)	AP2012006242A0 (sl)
AR (1)	AR079944A1 (sl)
AU (1)	AU2011208719C1 (sl)
BR (1)	BR112012018021B1 (sl)
CA (1)	CA2787566A1 (sl)
CO (1)	CO6571889A2 (sl)
CY (2)	CY1118875T1 (sl)
DK (1)	DK2525812T3 (sl)
EA (1)	EA028371B1 (sl)
EC (1)	ECSP12012105A (sl)
ES (1)	ES2614992T3 (sl)
FR (1)	FR17C1026I2 (sl)
GE (1)	GEP20156341B (sl)
HK (1)	HK1173957A1 (sl)
HR (1)	HRP20170613T1 (sl)
HU (2)	HUE032263T2 (sl)
IL (1)	IL219427B (sl)
LT (2)	LT2525812T (sl)
LU (1)	LUC00028I2 (sl)
MA (1)	MA33936B1 (sl)
ME (1)	ME02602B (sl)
MX (1)	MX2012008360A (sl)
MY (1)	MY162323A (sl)
NL (1)	NL300882I2 (sl)
NO (2)	NO2017034I1 (sl)
NZ (1)	NZ599508A (sl)
PE (1)	PE20121516A1 (sl)
PL (1)	PL2525812T3 (sl)
PT (1)	PT2525812T (sl)
RS (1)	RS55683B1 (sl)
SG (1)	SG182552A1 (sl)
SI (1)	SI2525812T1 (sl)
TN (1)	TN2012000366A1 (sl)
TW (1)	TWI513466B (sl)
UA (1)	UA110470C2 (sl)
UY (1)	UY33196A (sl)
WO (1)	WO2011089183A2 (sl)
ZA (1)	ZA201202876B (sl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR079944A1 (es) *	2010-01-20	2012-02-29	Boehringer Ingelheim Int	Anticuerpo neutralizante de la actividad de un anticoagulante
DK3252076T3 (da)	2011-01-14	2019-12-02	Univ California	Diagnostisk anvendelse af antistoffer mod ror-1-protein
EP2665751A1 (en) *	2011-01-19	2013-11-27	Bayer Intellectual Property GmbH	Binding proteins to inhibitors of coagulation factors
AP2013007046A0 (en) *	2011-03-30	2013-08-31	Boehringer Ingelheim Int	Anticoagulant antidotes
ES2569674T3 (es)	2011-11-29	2016-05-12	Perosphere, Inc.	Agentes de reversión de los anticoagulantes
CA2916421A1 (en)	2013-03-14	2014-09-25	Bayer Healthcare Llc	Monoclonal antibodies against antithrombin beta complexed with heparin
WO2015059159A1 (en) *	2013-10-25	2015-04-30	Boehringer Ingelheim International Gmbh	Anticoagulant antidotes
TW201623331A (zh) *	2014-03-12	2016-07-01	普羅帝納生物科學公司	抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
CN105223348A (zh) *	2014-05-26	2016-01-06	北京九强生物技术股份有限公司	人抗凝血酶iii的胶乳增强免疫比浊法检测试剂盒
EP2980218A1 (en) *	2014-07-30	2016-02-03	Rheinische Friedrich-Wilhelms-Universität Bonn	Aptamer thrombin complex for use as an antidote to direct acting thrombin inhibitors
ES2907190T3 (es) *	2014-07-31	2022-04-22	Haemonetics Corp	Detección de la reversión de un anticoagulante mediante pruebas de coagulación por ecarina y factor Xa
WO2016044645A1 (en) *	2014-09-17	2016-03-24	Elmaleh David R	Anticoagulant derivatives for cardiovascular imaging
WO2016107605A1 (zh)	2014-12-31	2016-07-07	昆明积大制药股份有限公司	药物组合物及其制备方法
US10449195B2 (en)	2016-03-29	2019-10-22	Shenzhen Pharmacin Co., Ltd.	Pharmaceutical formulation of palbociclib and a preparation method thereof
US11879014B2 (en)	2017-03-17	2024-01-23	Tusk Therapeutics Ltd.	Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
WO2019124468A1 (ja)	2017-12-24	2019-06-27	ノイルイミューン・バイオテック株式会社	ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ－７、及びｃｃｌ１９を発現する免疫担当細胞
KR20200131861A (ko)	2018-03-13	2020-11-24	터스크 테라퓨틱스 리미티드	종양 특이적 세포 고갈에 대한 항-cd25
WO2019217705A1 (en) *	2018-05-11	2019-11-14	Proplex Technologies, LLC	Binding proteins and chimeric antigen receptor t cells targeting gasp-1 granules and uses thereof
CN113195515A (zh)	2018-10-29	2021-07-30	华海美国公司	新的二肽类化合物及其用途
US20220175748A1 (en)	2019-03-06	2022-06-09	University Of Rochester	Anticoagulant compositions and uses thereof
CN114306245A (zh)	2020-09-29	2022-04-12	深圳市药欣生物科技有限公司	无定形固体分散体的药物组合物及其制备方法
TW202321311A (zh) *	2021-08-02	2023-06-01	日商諾伊爾免疫生物科技股份有限公司	與scFv等之連接子結合的抗體
US11446286B1 (en) *	2022-02-28	2022-09-20	King Faisal University	Treatment of fungal infections using dabigatran etexilate

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6087380A (en)	1949-11-24	2000-07-11	Boehringer Ingelheim Pharma Kg	Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
EP0281604B1 (en)	1986-09-02	1993-03-31	Enzon Labs Inc.	Single polypeptide chain binding molecules
AU634186B2 (en)	1988-11-11	1993-02-18	Medical Research Council	Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
DK0654085T3 (da) *	1992-01-23	1997-09-22	Merck Patent Gmbh	Monomere og dimere antistof-fragment-fusionsproteiner
DE4203965A1 (de)	1992-02-11	1993-08-12	Max Planck Gesellschaft	Antidot fuer hirudin und synthetische thrombininhibitoren
DK1589107T3 (da)	1992-08-21	2010-04-26	Univ Bruxelles	Immonuglobuliner uden lette kæder
ATE199392T1 (de)	1992-12-04	2001-03-15	Medical Res Council	Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
RU2139092C1 (ru)	1993-06-03	1999-10-10	Терапьютик Антибодиз Инк.	Фрагменты антител в терапии
AT404357B (de)	1995-06-13	1998-11-25	Immuno Ag	Prothrombin-derivate
DE19605126A1 (de)	1996-02-12	1997-08-14	Basf Ag	Thrombinmuteine als Antidot für Thrombininhibitoren
US6200955B1 (en)	1996-06-11	2001-03-13	Commonwealth Biotechnologies, Inc.	Heparin binding peptides
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
PE121699A1 (es)	1997-02-18	1999-12-08	Boehringer Ingelheim Pharma	Heterociclos biciclicos disustituidos como inhibidores de la trombina
CA2288992C (en)	1997-04-30	2012-06-12	Enzon, Inc.	Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
DE19729544A1 (de) *	1997-07-10	1999-01-14	Basf Ag	Ancrod spezifische monoklonale Antikörper, Antikörperfragmente, deren Mischung oder Derivate und deren Verwendung
US6440417B1 (en)	1998-11-06	2002-08-27	Conjuchem, Inc.	Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
US6624141B1 (en)	1999-03-17	2003-09-23	The Regents Of The University Of Michigan	Protamine fragment compositions and methods of use
AU2001266557A1 (en)	2000-04-12	2001-10-23	Human Genome Sciences, Inc.	Albumin fusion proteins
CN1268394C (zh)	2001-01-17	2006-08-09	特鲁比昂药品公司	结合域－免疫球蛋白融合蛋白
US20040097547A1 (en)	2001-04-16	2004-05-20	Taveras Arthur G.	3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20070031438A1 (en) *	2001-12-10	2007-02-08	Junghans Richard P	Antibodies as chimeric effector cell receptors against tumor antigens
US20050214857A1 (en)	2001-12-11	2005-09-29	Algonomics N.V.	Method for displaying loops from immunoglobulin domains in different contexts
ATE328906T1 (de)	2002-06-28	2006-06-15	Domantis Ltd	Dual-specifische liganden mit erhöhter halbwertszeit
EP3299393A1 (en)	2002-11-08	2018-03-28	Ablynx N.V.	Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
ATE414106T1 (de)	2003-06-30	2008-11-15	Domantis Ltd	Pegylierte single-domain-antikörper (dab)
HUE052423T2 (hu)	2007-09-28	2021-04-28	Alexion Pharma Inc	Az XA faktor inhibitorok antidótumai és ezek alkalmazási módszerei
AR070141A1 (es) *	2008-01-23	2010-03-17	Glenmark Pharmaceuticals Sa	Anticuerpos humanizados especificos para el factor von willebrand
TW201124143A (en)	2009-08-24	2011-07-16	Boehringer Ingelheim Int	Emergency interventions of active charcoal with dabigatran etexilate overdosing
AR079944A1 (es)	2010-01-20	2012-02-29	Boehringer Ingelheim Int	Anticuerpo neutralizante de la actividad de un anticoagulante

2011
- 2011-01-19 AR ARP110100179A patent/AR079944A1/es active IP Right Grant
- 2011-01-19 TW TW100102006A patent/TWI513466B/zh active
- 2011-01-20 HU HUE11703410A patent/HUE032263T2/en unknown
- 2011-01-20 EP EP16205771.5A patent/EP3195876A1/en not_active Withdrawn
- 2011-01-20 SI SI201131156A patent/SI2525812T1/sl unknown
- 2011-01-20 KR KR1020127019086A patent/KR101781787B1/ko active IP Right Grant
- 2011-01-20 AU AU2011208719A patent/AU2011208719C1/en active Active
- 2011-01-20 PT PT117034108T patent/PT2525812T/pt unknown
- 2011-01-20 PL PL11703410T patent/PL2525812T3/pl unknown
- 2011-01-20 UY UY0001033196A patent/UY33196A/es active IP Right Grant
- 2011-01-20 JP JP2012549355A patent/JP5575923B2/ja active Active
- 2011-01-20 EA EA201201016A patent/EA028371B1/ru active Protection Beyond IP Right Term
- 2011-01-20 MA MA35080A patent/MA33936B1/fr unknown
- 2011-01-20 PE PE2012000997A patent/PE20121516A1/es active IP Right Grant
- 2011-01-20 SG SG2012052445A patent/SG182552A1/en unknown
- 2011-01-20 CA CA2787566A patent/CA2787566A1/en not_active Abandoned
- 2011-01-20 GE GEAP201112836A patent/GEP20156341B/en unknown
- 2011-01-20 ES ES11703410.8T patent/ES2614992T3/es active Active
- 2011-01-20 ME MEP-2017-29A patent/ME02602B/me unknown
- 2011-01-20 US US13/010,403 patent/US8486398B2/en active Active
- 2011-01-20 WO PCT/EP2011/050749 patent/WO2011089183A2/en active Application Filing
- 2011-01-20 BR BR112012018021-5A patent/BR112012018021B1/pt active IP Right Grant
- 2011-01-20 EP EP11703410.8A patent/EP2525812B1/en active Active
- 2011-01-20 RS RS20170195A patent/RS55683B1/sr unknown
- 2011-01-20 DK DK11703410.8T patent/DK2525812T3/en active
- 2011-01-20 UA UAA201209779A patent/UA110470C2/ru unknown
- 2011-01-20 NZ NZ599508A patent/NZ599508A/en unknown
- 2011-01-20 LT LTEP11703410.8T patent/LT2525812T/lt unknown
- 2011-01-20 CN CN201180006616.4A patent/CN102711813B/zh active Active
- 2011-01-20 MY MYPI2012002840A patent/MY162323A/en unknown
- 2011-01-20 MX MX2012008360A patent/MX2012008360A/es active IP Right Grant
- 2011-01-20 AP AP2012006242A patent/AP2012006242A0/xx unknown
2012
- 2012-04-19 ZA ZA2012/02876A patent/ZA201202876B/en unknown
- 2012-04-25 IL IL219427A patent/IL219427B/en active IP Right Grant
- 2012-07-18 TN TNP2012000366A patent/TN2012000366A1/en unknown
- 2012-07-23 CO CO12123109A patent/CO6571889A2/es active IP Right Grant
- 2012-08-14 EC ECSP12012105 patent/ECSP12012105A/es unknown
2013
- 2013-01-23 HK HK13101025.2A patent/HK1173957A1/xx unknown
- 2013-06-13 US US13/916,994 patent/US9034822B2/en active Active
2014
- 2014-07-02 JP JP2014136811A patent/JP2014210794A/ja active Pending
2015
- 2015-04-13 US US14/684,576 patent/US20150210778A1/en not_active Abandoned
2017
- 2017-03-22 CY CY20171100361T patent/CY1118875T1/el unknown
- 2017-04-14 HR HRP20170613TT patent/HRP20170613T1/hr unknown
- 2017-07-06 NL NL300882C patent/NL300882I2/nl unknown
- 2017-07-10 CY CY2017025C patent/CY2017025I2/el unknown
- 2017-07-10 LT LTPA2017021C patent/LTC2525812I2/lt unknown
- 2017-07-10 FR FR17C1026C patent/FR17C1026I2/fr active Active
- 2017-07-11 NO NO2017034C patent/NO2017034I1/no unknown
- 2017-07-12 LU LU00028C patent/LUC00028I2/fr unknown
- 2017-07-13 HU HUS1700030C patent/HUS1700030I1/hu unknown
2022
- 2022-08-12 NO NO2022036C patent/NO2022036I1/no unknown

Also Published As

Publication number	Publication date
ZA201202876B (en)	2012-12-27
AU2011208719A1 (en)	2012-05-17
PE20121516A1 (es)	2012-11-24
GEP20156341B (en)	2015-08-10
AP2012006242A0 (en)	2012-04-30
NO2022036I1 (no)	2022-08-12
WO2011089183A2 (en)	2011-07-28
EP2525812A2 (en)	2012-11-28
JP5575923B2 (ja)	2014-08-20
IL219427B (en)	2018-05-31
LT2525812T (lt)	2017-02-27
LTPA2017021I1 (lt)	2017-07-25
KR101781787B1 (ko)	2017-09-26
FR17C1026I2 (fr)	2018-07-20
US20150210778A1 (en)	2015-07-30
UY33196A (es)	2011-08-31
ME02602B (me)	2017-06-20
LUC00028I2 (sl)	2017-09-25
JP2014210794A (ja)	2014-11-13
MA33936B1 (fr)	2013-01-02
PL2525812T3 (pl)	2017-07-31
CY2017025I1 (el)	2017-11-14
TN2012000366A1 (en)	2014-01-30
CY1118875T1 (el)	2018-01-10
US20130289248A1 (en)	2013-10-31
DK2525812T3 (en)	2017-02-27
KR20120128126A (ko)	2012-11-26
TWI513466B (zh)	2015-12-21
AR079944A1 (es)	2012-02-29
CN102711813B (zh)	2015-03-04
IL219427A0 (en)	2012-06-28
JP2013517317A (ja)	2013-05-16
HRP20170613T1 (hr)	2017-06-30
CN102711813A (zh)	2012-10-03
UA110470C2 (ru)	2016-01-12
EA201201016A1 (ru)	2013-02-28
HK1173957A1 (en)	2013-05-31
FR17C1026I1 (fr)	2017-09-08
SG182552A1 (en)	2012-08-30
ES2614992T3 (es)	2017-06-02
US20120027780A1 (en)	2012-02-02
US9034822B2 (en)	2015-05-19
CY2017025I2 (el)	2017-11-14
NO2017034I1 (no)	2017-07-11
CO6571889A2 (es)	2012-11-30
LTC2525812I2 (lt)	2019-05-10
HUS1700030I1 (hu)	2017-08-28
NL300882I2 (nl)	2017-07-20
PT2525812T (pt)	2017-04-26
NZ599508A (en)	2014-05-30
RS55683B1 (sr)	2017-07-31
EP2525812B1 (en)	2017-01-18
EA028371B1 (ru)	2017-11-30
BR112012018021B1 (pt)	2020-12-08
CA2787566A1 (en)	2011-07-28
AU2011208719C1 (en)	2017-07-13
EP3195876A1 (en)	2017-07-26
WO2011089183A3 (en)	2011-11-17
LUC00028I1 (sl)	2017-07-14
HUE032263T2 (en)	2017-09-28
ECSP12012105A (es)	2012-10-30
MY162323A (en)	2017-05-31
US8486398B2 (en)	2013-07-16
BR112012018021A2 (pt)	2017-06-20
MX2012008360A (es)	2012-08-08
TW201136606A (en)	2011-11-01

Publication	Publication Date	Title
HUS1700030I1 (hu)	2017-08-28	Véralvadásgátló-antidótumok
GB201322812D0 (en)	2014-02-05	No title
ZA201302364B (en)	2013-12-23	Auto-injector
ZA201302153B (en)	2013-11-27	Auto-injector
GB201304176D0 (en)	2013-04-24	No title
GB201508422D0 (en)	2015-07-01	No Title
GB201406982D0 (en)	2014-06-04	No title
GB201405882D0 (en)	2014-05-14	No title
GB201312107D0 (en)	2013-08-21	No title
IL227653A0 (en)	2013-09-30	Anticoagulant antidotes
EP2535065A4 (en)	2014-07-23	dialyzer
EP2976135A4 (en)	2017-01-18	Trampolines
GB201313383D0 (en)	2013-09-11	No title
GB201512453D0 (en)	2015-08-19	No title
GB201411386D0 (en)	2014-08-13	No title
GB201503046D0 (en)	2015-04-08	No title
GB201403810D0 (en)	2014-04-16	No title
GB2481890B (en)	2014-07-16	Balanced switch
GB201009261D0 (en)	2010-07-21	Trays
AU2011100252A4 (en)	2011-04-14	Catch the Coasters
GB201400705D0 (en)	2014-03-05	No title
GB201307218D0 (en)	2013-05-29	No title
AU2012904850A0 (en)	2012-11-22	Game
AU2012905329A0 (en)	2012-12-20	Trampolines
GB201216988D0 (en)	2012-11-07	No title